Coya Therapeutics, Inc.
COYA
$4.54
$0.255.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 11.10% | 2,078.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.10% | 2,078.67% | |||
| Cost of Revenue | 69.38% | -20.37% | |||
| Gross Profit | -251.45% | 118.50% | |||
| SG&A Expenses | 27.86% | -12.06% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 49.92% | -16.68% | |||
| Operating Income | -122.09% | 70.12% | |||
| Income Before Tax | -169.66% | 65.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -169.80% | 65.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -169.80% | 65.29% | |||
| EBIT | -122.09% | 70.12% | |||
| EBITDA | -122.52% | 70.19% | |||
| EPS Basic | -169.78% | 65.31% | |||
| Normalized Basic EPS | -145.48% | 73.75% | |||
| EPS Diluted | -169.78% | 65.31% | |||
| Normalized Diluted EPS | -145.48% | 73.75% | |||
| Average Basic Shares Outstanding | 0.06% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||